ArticleCureus2026
Psoriasiform Dermatitis Following JAK Inhibitor Therapy for Hidradenitis Suppurativa and Crohn's Disease.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Upadacitinib, a selective JAK1 inhibitor approved for hidradenitis suppurativa (HS) and Crohn's disease (CD), has been implicated in paradoxical inflammatory reactions; however, upadacitinib-induced psoriasiform dermatitis in patients treated for HS has not been previously described to the best of our knowledge. We report a 55-year-old woman with HS, CD, rheumatoid arthritis, and systemic lupus erythematosus, receiving upadacitinib 30 mg daily, who developed a pruritic erythematous scaly plaque on the lower back without personal or family history of psoriasis. Punch biopsy demonstrated psoriasiform dermatitis with acanthosis, focal hypogranulosis, uniform elongation of rete ridges, spongiosis, parakeratosis, and a superficial perivascular lymphocytic infiltrate. Given upadacitinib's established efficacy for both HS and CD, the drug was continued, and topical augmented betamethasone dipropionate was initiated, achieving adequate control at two-week follow-up. This case inverts the established paradigm in which JAK inhibitors serve as rescue agents for paradoxical reactions triggered by anti-TNF-α biologics. Comparable psoriasiform eruptions have been reported with baricitinib and tofacitinib, primarily in rheumatoid arthritis, a comorbidity present in our patient and an important interpretive caveat. We hypothesize that interferon-gamma (IFN-γ)-mediated STAT1 dysregulation intrinsic to HS pathogenesis may lower the threshold for JAK inhibitor-induced immune imbalance, although this mechanism remains speculative and warrants further investigation. Paradoxically, upadacitinib has also resolved psoriasiform eruptions in HS, underscoring the bidirectional and unpredictable nature of JAK1 inhibitor-mediated immune modulation. Psoriasiform dermatitis may represent a paradoxical cutaneous reaction to upadacitinib in patients with HS, warranting vigilant dermatologic monitoring and further investigation into individual susceptibility factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.